JUMP‐C: A randomized trial of mericitabine plus pegylated interferon alpha‐2a/ribavirin for 24 weeks in treatment‐naïve HCV genotype 1/4 patients

Mericitabine is a selective nucleoside analog inhibitor of the hepatitis C virus (HCV) NS5B RNA‐dependent RNA polymerase, with activity across all HCV genotypes. Treatment‐naïve patients infected with HCV genotype 1 or 4 were randomized to 24 weeks of double‐blind treatment with either mericitabine 1,000 mg (N = 81) or placebo (N = 85) twice‐daily (BID) in combination with pegylated interferon alpha‐2a (Peg‐IFNα‐2a)/ribavirin (RBV). Patients randomized to mericitabine with HCV RNA <15 IU/mL from week 4 to 22 (extended rapid virologic response; eRVR) stopped all treatment at week 24; all other patients continued Peg‐IFNα‐2a/RBV to complete 48 weeks of treatment. The primary efficacy endpoint was sustained virologic response (SVR; HCV RNA <15 IU/mL after 24 weeks of treatment‐free follow‐up). SVR was achieved in 56.8% (95% confidence interval [CI]: 45.9‐67.0) of mericitabine‐treated patients and 36.5% (95% CI: 27.0‐47.1) of placebo‐treated patients (Δ = 20.3%; 95% CI 5.5‐35.2). SVR rates were higher in mericitabine‐ than placebo‐treated patients when subdivided by IL28B genotype (CC, 77.8% versus 56.0%; non‐CC, 44.1% versus 16.2%) and hepatic fibrosis (noncirrhotic, 63.3% versus 41.9%; cirrhotic, 38.1% versus 21.7%). Overall relapse rates were 27.7% and 32.0% in mericitabine‐ and placebo‐treated patients, respectively. No evidence of NS5B S282T‐variant virus or phenotypic resistance to mericitabine was observed in the one patient who experienced partial response. No S282T variants were detected in any baseline samples. The safety profile of mericitabine was similar to that of, and fewer patients in the mericitabine than in the placebo group discontinued treatment for safety reasons. Conclusion: A 24‐week response‐guided combination regimen of mericitabine 1,000 mg BID plus Peg‐IFNα‐2a/RBV is well tolerated and more effective than a standard 48‐week course of Peg‐IFNα‐2a/RBV. (HEPATOLOGY 2013;58:514–523)

[1]  S. Zeuzem,et al.  PROPEL: A randomized trial of mericitabine plus peginterferon alpha‐2a/ribavirin therapy in treatment‐naïve HCV genotype 1/4 patients , 2013, Hepatology.

[2]  F. Carrat,et al.  8 SAFETY OF TELAPREVIR OR BOCEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA/RIBAVIRIN, IN CIRRHOTIC NON RESPONDERS. FIRST RESULTS OF THE FRENCH EARLY ACCESS PROGRAM (ANRS CO20-CUPIC) , 2012 .

[3]  P. Marcellin,et al.  1412 INTERFERON-FREE TREATMENT WITH A COMBINATION OF MERICITABINE AND DANOPREVIR/R WITH OR WITHOUT RIBAVIRIN IN TREATMENT-NAIVE HCV GENOTYPE 1-INFECTED PATIENTS , 2012 .

[4]  J. Pawlotsky,et al.  Review Resistance to Mericitabine, a Nucleoside Analogue Inhibitor of Hcv Rna-dependent Rna Polymerase , 2022 .

[5]  K. Reddy,et al.  Impact of HCV Protease-Inhibitor-Based Triple Therapy for Chronic HCV Genotype 1 Infection , 2011, Antiviral therapy.

[6]  M. Ghany,et al.  An Update on Treatment of Genotype 1 Chronic Hepatitis C Virus Infection: 2011 Practice Guideline by the American Association for the Study of Liver Diseases , 2011, Hepatology.

[7]  Michael Adler,et al.  Response-guided telaprevir combination treatment for hepatitis C virus infection. , 2011, The New England journal of medicine.

[8]  B. Bacon,et al.  Diagnosis and Management of Hemochromatosis: 2011 Practice Guideline by the American Association for the Study of Liver Diseases , 2011, Hepatology.

[9]  Geoffrey Dusheiko,et al.  Telaprevir for previously untreated chronic hepatitis C virus infection. , 2011, The New England journal of medicine.

[10]  O. Weiland,et al.  Telaprevir for retreatment of HCV infection. , 2011, The New England journal of medicine.

[11]  Stefan Zeuzem,et al.  Boceprevir for previously treated chronic HCV genotype 1 infection. , 2011, The New England journal of medicine.

[12]  Sprint Investigators,et al.  Boceprevir for Untreated Chronic HCV Genotype 1 Infection , 2011 .

[13]  M. Manns,et al.  Boceprevir for untreated chronic HCV genotype 1 infection. , 2011, The New England journal of medicine.

[14]  D. Harnois.  Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial , 2011 .

[15]  A. Kosaka,et al.  RG7128 alone or in combination with pegylated interferon-α2a and ribavirin prevents hepatitis C virus (HCV) Replication and selection of resistant variants in HCV-infected patients. , 2010, The Journal of infectious diseases.

[16]  Tom Chu,et al.  Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial , 2010, The Lancet.

[17]  J. Bernatchez,et al.  Inhibitors of the Hepatitis C Virus RNA-Dependent RNA Polymerase NS5B , 2010, Viruses.

[18]  Christoph Sarrazin,et al.  Resistance to direct antiviral agents in patients with hepatitis C virus infection. , 2010, Gastroenterology.

[19]  J. Symons,et al.  Selected Replicon Variants with Low-Level In Vitro Resistance to the Hepatitis C Virus NS5B Polymerase Inhibitor PSI-6130 Lack Cross-Resistance with R1479 , 2008, Antimicrobial Agents and Chemotherapy.

[20]  Klaus Klumpp,et al.  Characterization of the Metabolic Activation of Hepatitis C Virus Nucleoside Inhibitor β-d-2′-Deoxy-2′-fluoro-2′-C-methylcytidine (PSI-6130) and Identification of a Novel Active 5′-Triphosphate Species* , 2007, Journal of Biological Chemistry.

[21]  M. Otto,et al.  Inhibition of Hepatitis C Replicon RNA Synthesis by β-D-2′-deoxy-2′-fluoro-2′-C-Methylcytidine: A Specific Inhibitor of Hepatitis C Virus Replication , 2006, Antiviral chemistry & chemotherapy.

[22]  D. Hazuda,et al.  Characterization of Resistance to Non-obligate Chain-terminating Ribonucleoside Analogs That Inhibit Hepatitis C Virus Replication in Vitro* , 2003, Journal of Biological Chemistry.

[23]  Charles A. Lesburg,et al.  Crystal structure of the RNA-dependent RNA polymerase from hepatitis C virus reveals a fully encircled active site , 1999, Nature Structural Biology.